# PM8002 in the Treatment of Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct05918445/  
OnCo record `nct05918445` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of PM8002 in advanced solid tumours, run by Biotheus Inc., now recruiting.

## Summary

PM8002 in the Treatment of Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05918445 by Biotheus Inc., with 380 participants planned, started 2021-03-09 and due to reach its primary completion in 2025-11-30. Interventions recorded: PM8002.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05918445
- Phase: 1/2
- Setting: Phase Ib/IIa Safety and Efficacy of PM8002, a Bispecific Antibody Targeting PD-L1 and VEGF-A, as a Monotherapy in Patients With Advanced Solid Tumors
- Sponsor: Biotheus Inc.
- Enrolled: 380

## Sources

- ClinicalTrials.gov NCT05918445: https://clinicaltrials.gov/study/NCT05918445

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [PM8002](https://onco.cc/drugs/pm8002/)
- companies: [BioNTech](https://onco.cc/companies/biontech/)

---
JSON: https://onco.cc/api/v1/entities/nct05918445.json